Selected research
Market Structure
Global Binge Eating Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Binge Eating Disorder Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Binge Eating Disorder Drug include Novo Nordisk, Roche, Sunovion Pharmaceuticals, Opiant Pharmaceuticals, Omeros Corp, Heptares and Chronos Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Binge Eating Disorder Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Binge Eating Disorder Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Binge Eating Disorder Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Binge Eating Disorder Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Binge Eating Disorder Drug Segment by Company
Novo Nordisk
Roche
Sunovion Pharmaceuticals
Opiant Pharmaceuticals
Omeros Corp
Heptares
Chronos Therapeutics
Binge Eating Disorder Drug Segment by Type
Anti-obesity Medications
Anticonvulsants
Antidepressants
Binge Eating Disorder Drug Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Binge Eating Disorder Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Binge Eating Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Binge Eating Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Binge Eating Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Binge Eating Disorder Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Binge Eating Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Binge Eating Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Binge Eating Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-obesity Medications
- Anticonvulsants
- Antidepressants
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Novo Nordisk
- Roche
- Sunovion Pharmaceuticals
- Opiant Pharmaceuticals
- Omeros Corp
- Heptares
- Chronos Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Binge Eating Disorder Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Binge Eating Disorder Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Binge Eating Disorder Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Binge Eating Disorder Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Binge Eating Disorder Drug Market Dynamics
- 2.1 Binge Eating Disorder Drug Industry Trends
- 2.2 Binge Eating Disorder Drug Industry Drivers
- 2.3 Binge Eating Disorder Drug Industry Opportunities and Challenges
- 2.4 Binge Eating Disorder Drug Industry Restraints
3 Binge Eating Disorder Drug Market by Manufacturers
- 3.1 Global Binge Eating Disorder Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Binge Eating Disorder Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Binge Eating Disorder Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Binge Eating Disorder Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Binge Eating Disorder Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Binge Eating Disorder Drug Manufacturers, Product Type & Application
- 3.7 Global Binge Eating Disorder Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Binge Eating Disorder Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Binge Eating Disorder Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Binge Eating Disorder Drug Tier 1, Tier 2, and Tier 3
4 Binge Eating Disorder Drug Market by Type
- 4.1 Binge Eating Disorder Drug Type Introduction
- 4.1.1 Anti-obesity Medications
- 4.1.2 Anticonvulsants
- 4.1.3 Antidepressants
- 4.2 Global Binge Eating Disorder Drug Sales by Type
- 4.2.1 Global Binge Eating Disorder Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Binge Eating Disorder Drug Sales by Type (2021-2032)
- 4.2.3 Global Binge Eating Disorder Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Binge Eating Disorder Drug Revenue by Type
- 4.3.1 Global Binge Eating Disorder Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Binge Eating Disorder Drug Revenue by Type (2021-2032)
- 4.3.3 Global Binge Eating Disorder Drug Revenue Market Share by Type (2021-2032)
5 Binge Eating Disorder Drug Market by Application
- 5.1 Binge Eating Disorder Drug Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Hospital Pharmacies
- 5.2 Global Binge Eating Disorder Drug Sales by Application
- 5.2.1 Global Binge Eating Disorder Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Binge Eating Disorder Drug Sales by Application (2021-2032)
- 5.2.3 Global Binge Eating Disorder Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Binge Eating Disorder Drug Revenue by Application
- 5.3.1 Global Binge Eating Disorder Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Binge Eating Disorder Drug Revenue by Application (2021-2032)
- 5.3.3 Global Binge Eating Disorder Drug Revenue Market Share by Application (2021-2032)
6 Global Binge Eating Disorder Drug Sales by Region
- 6.1 Global Binge Eating Disorder Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Binge Eating Disorder Drug Sales by Region (2021-2032)
- 6.2.1 Global Binge Eating Disorder Drug Sales by Region (2021-2026)
- 6.2.2 Global Binge Eating Disorder Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Binge Eating Disorder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Binge Eating Disorder Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Binge Eating Disorder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Binge Eating Disorder Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Binge Eating Disorder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Binge Eating Disorder Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Binge Eating Disorder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Binge Eating Disorder Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Binge Eating Disorder Drug Revenue by Region
- 7.1 Global Binge Eating Disorder Drug Revenue by Region
- 7.1.1 Global Binge Eating Disorder Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Binge Eating Disorder Drug Revenue by Region (2021-2026)
- 7.1.3 Global Binge Eating Disorder Drug Revenue by Region (2027-2032)
- 7.1.4 Global Binge Eating Disorder Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Binge Eating Disorder Drug Revenue (2021-2032)
- 7.2.2 North America Binge Eating Disorder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Binge Eating Disorder Drug Revenue (2021-2032)
- 7.3.2 Europe Binge Eating Disorder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Binge Eating Disorder Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Binge Eating Disorder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Binge Eating Disorder Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Binge Eating Disorder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novo Nordisk
- 8.1.1 Novo Nordisk Company Information
- 8.1.2 Novo Nordisk Business Overview
- 8.1.3 Novo Nordisk Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novo Nordisk Binge Eating Disorder Drug Product Portfolio
- 8.1.5 Novo Nordisk Recent Developments
- 8.2 Roche
- 8.2.1 Roche Company Information
- 8.2.2 Roche Business Overview
- 8.2.3 Roche Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Roche Binge Eating Disorder Drug Product Portfolio
- 8.2.5 Roche Recent Developments
- 8.3 Sunovion Pharmaceuticals
- 8.3.1 Sunovion Pharmaceuticals Company Information
- 8.3.2 Sunovion Pharmaceuticals Business Overview
- 8.3.3 Sunovion Pharmaceuticals Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sunovion Pharmaceuticals Binge Eating Disorder Drug Product Portfolio
- 8.3.5 Sunovion Pharmaceuticals Recent Developments
- 8.4 Opiant Pharmaceuticals
- 8.4.1 Opiant Pharmaceuticals Company Information
- 8.4.2 Opiant Pharmaceuticals Business Overview
- 8.4.3 Opiant Pharmaceuticals Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Opiant Pharmaceuticals Binge Eating Disorder Drug Product Portfolio
- 8.4.5 Opiant Pharmaceuticals Recent Developments
- 8.5 Omeros Corp
- 8.5.1 Omeros Corp Company Information
- 8.5.2 Omeros Corp Business Overview
- 8.5.3 Omeros Corp Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Omeros Corp Binge Eating Disorder Drug Product Portfolio
- 8.5.5 Omeros Corp Recent Developments
- 8.6 Heptares
- 8.6.1 Heptares Company Information
- 8.6.2 Heptares Business Overview
- 8.6.3 Heptares Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Heptares Binge Eating Disorder Drug Product Portfolio
- 8.6.5 Heptares Recent Developments
- 8.7 Chronos Therapeutics
- 8.7.1 Chronos Therapeutics Company Information
- 8.7.2 Chronos Therapeutics Business Overview
- 8.7.3 Chronos Therapeutics Binge Eating Disorder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Chronos Therapeutics Binge Eating Disorder Drug Product Portfolio
- 8.7.5 Chronos Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Binge Eating Disorder Drug Value Chain Analysis
- 9.1.1 Binge Eating Disorder Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Binge Eating Disorder Drug Production Mode & Process
- 9.2 Binge Eating Disorder Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Binge Eating Disorder Drug Distributors
- 9.2.3 Binge Eating Disorder Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst